0.24
-0.0155(-6.11%)
Currency In USD
| Previous Close | 0.25 |
| Open | 0.26 |
| Day High | 0.26 |
| Day Low | 0.24 |
| 52-Week High | 2.1 |
| 52-Week Low | 0.22 |
| Volume | 720,558 |
| Average Volume | 3.36M |
| Market Cap | 54.96M |
| PE | -0.95 |
| EPS | -0.25 |
| Moving Average 50 Days | 0.28 |
| Moving Average 200 Days | 0.59 |
| Change | -0.02 |
If you invested $1000 in Renovaro Biosciences Inc. (RENB) since IPO date, it would be worth $40.34 as of August 31, 2025 at a share price of $0.238. Whereas If you bought $1000 worth of Renovaro Biosciences Inc. (RENB) shares 5 years ago, it would be worth $58.33 as of August 31, 2025 at a share price of $0.238.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
GlobeNewswire Inc.
Jun 03, 2025 1:15 PM GMT
Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a clinical-stage precision medicine company, tod
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
GlobeNewswire Inc.
May 22, 2025 7:12 PM GMT
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedit
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
GlobeNewswire Inc.
May 22, 2025 3:05 PM GMT
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedit